BC Week In Review | Jan 18, 2019
Company News

MD Anderson collaborating with Ascentage, Nanobiotix on clinical testing of cancer assets

The University of Texas MD Anderson Cancer Center unveiled two new partnerships with China's Ascentage Pharma Group International (Suzhou, China) and France's Nanobiotix S.A. (Euronext:NANO) for clinical testing of their respective cancer assets. MD Anderson's...
BC Extra | Jan 7, 2019
Politics & Policy

Bipartisan bill to streamline U.S. response to foreign theft of IP may hasten clarity on biotech impact

As the biopharma industry awaits guidance from the government on the scope and potential impact of proposed technology export controls, a new congressional bill could help speed the process. Members of the Senate Select Committee...
BioCentury | Jan 13, 2017

Advancing apoptosis

A RMB500 million ($72 million) series B round will enable Ascentage Pharma Group Corp. Ltd. to generate clinical proof-of-concept data for two to three cancer candidates in three years. Future Industry Investment Fund led the...
BC Innovations | Jun 9, 2016

Sanofi's post-reconstruction era

Lauren Martz, Senior Writer  Five years after taking the helm as Sanofi 's president of global R&D, Elias Zerhouni is rounding out his strategy to revamp the division and rebuild the pipeline with the appointment...
BC Extra | Aug 14, 2015
Financial News

Ascentage Pharma raises $15.5M in series A

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) raised $15.5 million in a series A round led by Oriza Seed Capital and YuanMing Capital. EFung Capital; BioVenture Capital; Grains Valley Venture Capital; and undisclosed investors...
Items per page:
1 - 5 of 5